What is GLP-1, and what does it do?
GLP-1 stands for glucagon-like peptide-1. That is a mouthful, so think of it simply as a messenger. It is a hormone — a chemical messenger that travels in your blood — and your gut (your stomach and intestines) releases it right after you eat.
GLP-1 has a few jobs, all about handling the meal you just had. It nudges your body to release a little more insulin, the substance that helps move sugar out of your blood and into your cells. It quiets a second hormone called glucagon, whose job is the opposite — glucagon tells your liver to put more sugar into your blood. GLP-1 also slows down how fast your stomach empties, and it tells your brain that you are full, so you stop eating sooner.
There is one catch. Your own GLP-1 does not last long at all. Your body breaks it down within minutes. So that helpful "I am full, and my blood sugar is handled" signal fades fast, almost as soon as it arrives.
What is a 'GLP-1 receptor agonist'?
Let us take that name apart, because it sounds more complicated than it is. A "receptor" is like a lock on the surface of a cell. GLP-1 is the key that fits that lock. When the key turns the lock, the cell gets the message and acts on it.
An "agonist" is just a word for something that turns the lock the same way the real key does. So a GLP-1 receptor agonist is a medicine built to act like your natural GLP-1 — it turns the same lock and sends the same message.
The clever part is timing. Your own GLP-1 disappears in minutes. These medicines are built to last about a week instead. Because the message stays switched on far longer, the "I am full" and "blood sugar handled" effects keep working steadily, day after day, between doses. That is the whole point of the design.
How do these medicines actually cause weight loss and lower blood sugar?
Start with blood sugar. When you eat, sugar from food enters your blood. GLP-1 signaling nudges your body to release more insulin, which helps clear that sugar out of the blood. At the same time it quiets glucagon, the hormone that would otherwise push more sugar in. Less sugar going in, more help clearing it out — so blood sugar runs lower and steadier. This is why this kind of medicine was first used for type 2 diabetes, a condition where blood sugar runs too high.
Now the weight side, which comes down to eating less without a daily fight. Because the medicine slows your stomach, food stays with you longer, so you feel full sooner and stay full longer. And because it quiets hunger in the brain, you simply want less food and think about it less often.
Put those together and most people eat less over the day, almost automatically. Eating less, week after week, is what leads to weight loss. The medicine is not burning fat directly. It is turning hunger down so that eating less stops feeling like a constant battle.
One, two, or three signals: how the drugs differ
Here is the part that confuses almost everyone. These medicines do not all copy the same number of gut signals. Some copy one, some copy two, and a newer one copies three. Picture light switches in a room: copying more signals is like flipping more switches at once.
Semaglutide copies one signal: GLP-1. It is one switch. In a large study, people on semaglutide lost about 14.9 percent of their body weight over 68 weeks. Semaglutide is approved by the FDA — that is the part of the US government that checks medicines are safe and that they work — and it is sold under brand names you may know, like Ozempic for type 2 diabetes and Wegovy for weight.
Tirzepatide copies two signals: GLP-1 plus a second gut messenger called GIP. That is two switches. In its own large study, people on the 15 milligram dose lost about 20.9 percent of their body weight over 72 weeks. Tirzepatide is also FDA-approved, and you may know it as Mounjaro or Zepbound.
Retatrutide copies three signals: GLP-1, GIP, and glucagon. That is three switches. Here is the important part to be clear about: retatrutide is still being tested in studies. It is investigational — not approved by the FDA, and not something you can buy. "Still being studied" and "approved for use" are very different things, and it matters to keep them apart.
What are the common side effects, and why?
The most common side effects with this whole family of medicines are stomach-related: feeling sick (nausea), diarrhea, throwing up, or being constipated. They are described as dose-dependent, which simply means they tend to show up more at higher doses.
Once you remember how the medicine works, this makes sense. It slows your stomach down on purpose. So food sits longer, and your gut has to adjust to the new pace. That adjustment is what your tummy is reacting to.
This is also why doctors usually start at a low dose and raise it slowly. Going up gradually gives your stomach time to get used to the change, and the side effects tend to ease as your body settles in. Even so, everyone is different, and side effects are a real thing to talk through with a doctor rather than push through alone.
Keeping track of it all with PeptidePanel
If a doctor decides one of these medicines is right for a person and prescribes it, there is real day-to-day stuff to keep track of: when the next dose is due, how weight is trending, and the lab numbers a doctor watches over time. That is easy to lose track of in your head.
PeptidePanel is a simple tracking tool for exactly that. It records the plan a doctor set, charts the results, and reminds you when something is due. It does not sell, supply, or recommend any medicine, and nothing here is medical advice. The decision to start any GLP-1 medicine — and which one — belongs to you and a licensed clinician who knows your full history. PeptidePanel is just the notebook that keeps that plan organized.